UMIN-CTR Clinical Trial
| Unique ID issued by UMIN | UMIN000017751 |
|---|---|
| Receipt number | R000019487 |
| Scientific Title | Phase I/II study of gemcitabine and nab-paclitaxel with radiation therapy in patients with pancreatic cancer. |
| Date of disclosure of the study information | 2015/05/31 |
| Last modified on | 2019/07/14 16:28:11 |
* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments
Basic information
Public title
Phase I/II study of gemcitabine and nab-paclitaxel with radiation therapy in patients with pancreatic cancer.
Acronym
Phase I/II study of GEM + nab-PTX + radiation therapy in patients with pancreatic cancer.
Scientific Title
Phase I/II study of gemcitabine and nab-paclitaxel with radiation therapy in patients with pancreatic cancer.
Scientific Title:Acronym
Phase I/II study of GEM + nab-PTX + radiation therapy in patients with pancreatic cancer.
Region
| Japan |
Condition
Condition
pancreatic cancer
Classification by specialty
| Hepato-biliary-pancreatic surgery |
Classification by malignancy
Malignancy
Genomic information
NO
Objectives
Narrative objectives1
Estimate the maximum tolerated dose(MTD) and recommended dose(RD), and evaluate the efficacy and tolerability of chemoradiotherapy of GEM with nab-PTX for pancreatic cancer.
Basic objectives2
Safety,Efficacy
Basic objectives -Others
Trial characteristics_1
Trial characteristics_2
Developmental phase
Assessment
Primary outcomes
(PhaseI)
Estimate the maximum tolerated dose(MTD) and recommended dose(RD)
(PhaseII)
Response rate
Key secondary outcomes
Base
Study type
Interventional
Study design
Basic design
Single arm
Randomization
Non-randomized
Randomization unit
Blinding
Open -no one is blinded
Control
Historical
Stratification
Dynamic allocation
Institution consideration
Blocking
Concealment
Intervention
No. of arms
1
Purpose of intervention
Treatment
Type of intervention
| Medicine |
Interventions/Control_1
(GEM,nab-PTX)
GEM and nab-PTX are administered intravenously in each dosage of level at day 1,8,22 and 29.
(Radiation)
Radiation is delivered a total dose of 50.4 Gy(28 fractions of1.8 Gy).
Interventions/Control_2
Interventions/Control_3
Interventions/Control_4
Interventions/Control_5
Interventions/Control_6
Interventions/Control_7
Interventions/Control_8
Interventions/Control_9
Interventions/Control_10
Eligibility
Age-lower limit
| 20 | years-old | <= |
Age-upper limit
| 80 | years-old | > |
Gender
Male and Female
Key inclusion criteria
(1) locally advanced pancreatic cancer without distant metastasis
(2) with no prior treatment(chemotherapy or radiation therapy) to pancreatic cancer
(3) Radiotherapist judges that we can include primary tumor and all lymph node metastases in the radiation field of 10cm *10cm by abdominal CT or MRI.
(4) evaluable lesion is confirmed with objective documents such as CT or MRI, the X-ray examination within 28 days before registration.
(5) age: >=20,80<
(6) ECOG P.S. 0-1
(7) sufficient function of important organs
WBC: >=3,500/mm3
Neut:>=2000/mm3
Platelet: >=100,000/mm3
Hem: >=9.0g/dl
Alb:>=3.0g/dL
AST, ALT: <= 100IU/l((or 150U/L if biliary drainage were present)
sT.bil: <=2.0mg/dl(or <=3.0mg/dl if biliary drainage were present)
serum Cr: <= Upper limit of normal
(8)no abnormal finding by cardiac electrogram within 28 days before registration.
(9)written informed consent
Key exclusion criteria
(1)bowel movement control is difficult, because of watery diarrhea and chronic diarrhea.
(2)Interstitial pneumonia or pulmonary fibrosis diagnosed by chest X-ray and with symptom
(3)Pleural effusion or ascitic fluid accumulates
(4)with clinically important infection
(5)has active carcinoma except carcinoma in situ
(6)with gastrointestinal active ulcer
(7)sever complication(heart failure, renal failure,liver failure,intestinal paralysis,uncontrollable diabetes etc)
(8)severe mental disorder
(9)severe drug allergy
(10)pregnant women or during the nursing, women who like be pregnant and willing to get pregnant
(11)doctors decision not to be registered to this study
Target sample size
30
Research contact person
Name of lead principal investigator
| 1st name | |
| Middle name | |
| Last name | Osamu Itano |
Organization
Department of Surgery, Keio University School of Medicine
Division name
Department of Surgery
Zip code
Address
Shinanomachi 35, shinjuku-ku
TEL
0333531211
contact@keio-hbpts.jp
Public contact
Name of contact person
| 1st name | |
| Middle name | |
| Last name | Minoru Kitago |
Organization
Department of Surgery, Keio University School of Medicine
Division name
Department of Surgery
Zip code
Address
Shinanomachi 35, shinjuku-ku
TEL
0333531211
Homepage URL
contact@keio-hbpts.jp
Sponsor or person
Institute
Department of Surgery, Keio University School of Medicine
Institute
Department
Personal name
Funding Source
Organization
Department of Surgery, Keio University School of Medicine
Organization
Division
Category of Funding Organization
Self funding
Nationality of Funding Organization
Other related organizations
Co-sponsor
Name of secondary funder(s)
IRB Contact (For public release)
Organization
Address
Tel
Secondary IDs
Secondary IDs
NO
Study ID_1
Org. issuing International ID_1
Study ID_2
Org. issuing International ID_2
IND to MHLW
Institutions
Institutions
Other administrative information
Date of disclosure of the study information
| 2015 | Year | 05 | Month | 31 | Day |
Related information
URL releasing protocol
Publication of results
Unpublished
Result
URL related to results and publications
Number of participants that the trial has enrolled
Results
Results date posted
Results Delayed
Results Delay Reason
Date of the first journal publication of results
Baseline Characteristics
Participant flow
Adverse events
Outcome measures
Plan to share IPD
IPD sharing Plan description
Progress
Recruitment status
Terminated
Date of protocol fixation
| 2015 | Year | 02 | Month | 27 | Day |
Date of IRB
| 2011 | Year | 08 | Month | 31 | Day |
Anticipated trial start date
| 2015 | Year | 05 | Month | 20 | Day |
Last follow-up date
| 2018 | Year | 11 | Month | 16 | Day |
Date of closure to data entry
Date trial data considered complete
Date analysis concluded
Other
Other related information
Management information
Registered date
| 2015 | Year | 05 | Month | 31 | Day |
Last modified on
| 2019 | Year | 07 | Month | 14 | Day |
Link to view the page
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000019487
